NewAmsterdam Pharma (NAMS) Total Liabilities (2021 - 2026)

NewAmsterdam Pharma has reported Total Liabilities for 6 years, with the latest figure at $67.4 million in Q1 2026.

• Quarterly Total Liabilities rose 64.24% year-over-year to $67.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $67.4 million (up 64.24% YoY) and the FY2025 annual result came in at $85.9 million, down 19.85% from the prior year.
• Total Liabilities declined to $67.4 million in Q1 2026 per NAMS's latest filing, from $85.9 million in the prior quarter.
• Over five years, Total Liabilities peaked at $542.3 million in Q4 2022 and troughed at $36.6 million in Q2 2025.
• A 5-year average of $142.2 million and a median of $63.9 million in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities jumped 693.03% in 2022, then sank 89.18% in 2023.
• Over 5 years, Total Liabilities stood at $542.3 million in 2022, then tumbled by 89.18% to $58.7 million in 2023, then surged by 82.47% to $107.1 million in 2024, then retreated by 19.85% to $85.9 million in 2025, then slipped by 21.47% to $67.4 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $67.4 million, $85.9 million, and $58.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.